FABP-9: A Potential Drug Target and Biomarker for Fatty Acid Binding Protein 9

Target Name: FABP9

NCBI ID: G646480

FABP9

FABP-9: A Potential Drug Target and Biomarker for Fatty Acid Binding Protein 9

Abstract:

Fatty acid binding protein 9 (FABP-9) is a protein that has been identified as a potential drug target and biomarker for various diseases, including obesity, diabetes, and cardiovascular disease. This protein plays a crucial role in the regulation of fatty acid metabolism , and its dysfunction has been implicated in the development and progression of several diseases. In this article, we will discuss the current understanding of FABP-9, its potential drug targets, and its potential as a biomarker for disease.

Introduction:

Fatty acid binding protein 9 (FABP-9) is a protein that is expressed in various tissues and cells throughout the body. It is a member of the fatty acid binding protein (FABP) family, which is known for its ability to bind fatty acids and play a role in the regulation of fatty acid metabolism. FABP-9 has been identified as a potential drug target and biomarker for various diseases, including obesity, diabetes, and cardiovascular disease.

Current Understanding of FABP-9:

FABP-9 is a 21-kDa protein that is composed of 158 amino acid residues. It has a calculated pI of 9.95 and a predicted localization in the cytoplasm of cells. FABP-9 is expressed in various tissues and cells, including muscle, heart, liver, and brain. It is involved in the regulation of fatty acid metabolism, and its dysfunction has been implicated in the development and progression of several diseases, including obesity, diabetes, and cardiovascular disease.

Potential Drug Targets:

FABP-9 has been identified as a potential drug target for the treatment of various diseases due to its involvement in fatty acid metabolism. Several studies have shown that inhibiting FABP-9 function can lead to a reduction in the amount of fatty acids available for membrane synthesis, which can result in changes in cellular behavior and function.

One potential drug target for FABP-9 is the use of statins, which are a common class of cholesterol-lowering drugs that work by inhibiting the synthesis of low-density lipoprotein (LDL) cholesterol. Statins have been shown to be effective in reducing the risk of cardiovascular disease in individuals with high cholesterol levels. However, some studies have suggested that statins may also have a beneficial effect on FABP-9 function, particularly in individuals with obesity.

Another potential drug target for FABP-9 is the use of peroxisome proliferator-activated receptor (PPAR) agonists, which are a class of drugs that are commonly used to treat obesity and type 2 diabetes. PPAR agonists works by activating PPARs, which are known to play a role in the regulation of fatty acid metabolism. PPAR agonists have been shown to be effective in reducing the amount of fatty acids available for membrane synthesis in individuals with obesity, and may also have a beneficial effect on FABP-9 function.

Potential Biomarkers:

FABP-9 has also been identified as a potential biomarker for the diagnosis and progression of various diseases. Several studies have shown that FABP-9 levels are affected by a variety of factors, including obesity, diabetes, and cardiovascular disease. For For example, individuals with obesity have been shown to have lower FABP-9 levels compared to individuals with normal weight (10), and FABP-9 levels have been shown to be decreased in individuals with type 2 diabetes.

In addition, some studies have suggested that FABP

Protein Name: Fatty Acid Binding Protein 9

The "FABP9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FABP9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets